Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals (NEU) has appointed Jon Pilcher and Patrick Davies as its Chief Executive Officer and non-executive Chair
  • These appointments follow Executive Chairman Richard Treagus’ decision to leave after over seven years in the role
  • Newly appointed CEO, Jon Pilcher, has been the Chief Financial Officer since 2013 and Neuren believes he’s ideal for the new role
  • Mr Davies joined the company a little more recently, however, he brings more than 10 years of leadership experience
  • Neuren is down a slight 1.19 per cent and shares are trading for $1.66 each

Neuren Pharmaceuticals (NEU) has appointed Jon Pilcher and Patrick Davies as its Chief Executive Officer and non-executive Chair.

These appointments follow Executive Chairman Richard Treagus’ decision to leave after over seven years in the role. Richard claims he wants to focus on other business interests.

Newly-appointed CEO, Jon, has consistently played a key role alongside Richard at Neuren and has established strong relationships with business partners and investors.

Jon has been with the company since 2013 as the Chief Financial Officer and, according to Neuren, is “ideally suited to lead Neuren as it moves forward to realise the value of two drugs across multiple childhood disorders with urgent unmet need”.

“Neuren is in a strong position with trofinetide in phase three under a productive partnership with ACADIA and NNZ-2591 now in clinical trials. We have three large value drivers in the near-term and the Neuren team is highly motivated to achieve positive outcomes for both patients and shareholders,” Jon said.

Patrick joined the company more recently, in 2018, as the non-executive Director. He was the CEO of EBOS Group (formerly Symbion) for 10 years. During this time, the company’s enterprise value grew from $450 million to more than $3.1 billion.

“On behalf of the board and management, we thank Richard for his commitment and passion over many years that has led Neuren to its current position of strength and wish him well in his other endeavours,” Patrick said.

“It has been a privilege to lead the business and I have every confidence that Jon and the management team will continue to do a truly outstanding job, as they always have,” Richard stated.

To ensure a smooth transition, Richard will be available to assist the board and management as these changes are implemented.

Neuren is down a slight 1.19 per cent and shares are trading for $1.66 each at 10:19 am AEST.

NEU by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.